Post Profile

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen.
read more


Related Posts

Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-free Survival For Patients With Relapsed/refractory Mantle Cell Lymphoma

Health : Medical News Today

Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients with relapsed and/or refractory (failed front line therapy and unresponsive to most recent treat...

Updated Survival Data From Three Phase II Ipilimumab Studies Showed Almost Half Of Previously Treated Metastatic Melanoma Patients Alive Beyond 1 Year

Health : Medical News Today

Bristol-Myers Squibb Company (NYSE: BMY) announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV), who had previously been treated. Study results show ...

RTOG to Announce Initial Results of an International Phase III Clinical Trial for Newly Diagnosed Brain Tumors

Health : Newswise Medical News

In the randomized trial, RTOG 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma, no significant improvement in overall patient survival o...

Adjuvant Ipilimumab effects survival after high risk lymph node and melanoma resection

Academics / General Science : ScienceDaily: Science Society

Adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, research indicates, but that this treatment was also associated with a h...

FDA approves Adjuvant Yervoy in melanoma based on results of EORTC trial 18071

Academics / General Science : Science Codex

Based on the results of EORTC trial 18071, the FDA expanded the approval of Yervoy (ipilimumab) in melanoma to include adjuvant treatment of patients with stage 3 melanoma at high risk of recurrence following complete resection. EOR...


Copyright © 2016 Regator, LLC